We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Union Pacific (UNP) Hurt by Sluggish Volumes & High Debts
Read MoreHide Full Article
Recently, we issued an updated research report on Union Pacific Corporation (UNP - Free Report) . The company is witnessing sluggish overall volumes (measured by total revenue carload) due to weakness in key divisions. Due to weak volumes, freight revenues, which account for a bulk of its top line, are declining. Notably, freight revenues were down 4% in the first nine months of 2019.
The same is likely to affect Union Pacific’s fourth-quarter results, scheduled to be released on Jan 23, 2020. In fact, the company issued a drab forecast for overall volumes at the Credit Suisse 7th Annual Industrial Conference in December, thanks to headwinds ranging from trade tensions to economic slowdown.
The company’s chief financial officer, Robert Knight, stated that overall volumes for the fourth quarter of 2019 are expected to decrease a little more than 10% on a year-over-year basis. At the same conference, Union Pacific stated that the top line for the December quarter is anticipated to decline by a similar percentage as volumes.
Moreover, its high debt levels are concerning. Notably, the debt/EBITDA ratio (adjusted) increased to 2.6 as of Sep 30, 2019, from 2.3 at 2018-end. Additionally, the massive capex might be a spoilsport.
Due to the above-mentioned headwinds, shares of Union Pacific have underperformed the S&P 500 index over the past six months. The stock has gained 5.8%, while the index appreciated 9.8% in the same time frame.
Estimate Revisions & Zacks Rank
Downward estimate revisions highlight the pessimism surrounding the stock. The Zacks Consensus Estimate for fiscal 2020 earnings has been revised 1.7% downward over the past 60 days.
Given this bleak backdrop, Union Pacific’s Zacks Rank #4 (Sell) is well justified.
Shares of Hawaiian Holdings, Ryanair Holdings and GATX have gained more than 12%, 21% and 19%, respectively, in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Union Pacific (UNP) Hurt by Sluggish Volumes & High Debts
Recently, we issued an updated research report on Union Pacific Corporation (UNP - Free Report) . The company is witnessing sluggish overall volumes (measured by total revenue carload) due to weakness in key divisions. Due to weak volumes, freight revenues, which account for a bulk of its top line, are declining. Notably, freight revenues were down 4% in the first nine months of 2019.
The same is likely to affect Union Pacific’s fourth-quarter results, scheduled to be released on Jan 23, 2020. In fact, the company issued a drab forecast for overall volumes at the Credit Suisse 7th Annual Industrial Conference in December, thanks to headwinds ranging from trade tensions to economic slowdown.
The company’s chief financial officer, Robert Knight, stated that overall volumes for the fourth quarter of 2019 are expected to decrease a little more than 10% on a year-over-year basis. At the same conference, Union Pacific stated that the top line for the December quarter is anticipated to decline by a similar percentage as volumes.
Moreover, its high debt levels are concerning. Notably, the debt/EBITDA ratio (adjusted) increased to 2.6 as of Sep 30, 2019, from 2.3 at 2018-end. Additionally, the massive capex might be a spoilsport.
Due to the above-mentioned headwinds, shares of Union Pacific have underperformed the S&P 500 index over the past six months. The stock has gained 5.8%, while the index appreciated 9.8% in the same time frame.
Estimate Revisions & Zacks Rank
Downward estimate revisions highlight the pessimism surrounding the stock. The Zacks Consensus Estimate for fiscal 2020 earnings has been revised 1.7% downward over the past 60 days.
Given this bleak backdrop, Union Pacific’s Zacks Rank #4 (Sell) is well justified.
Stocks to Consider
Investors interested in the Zacks Transportation sector can consider Hawaiian Holdings (HA - Free Report) , Ryanair Holdings (RYAAY - Free Report) and GATX Corporation (GATX - Free Report) . While Hawaiian Holdings and Ryanair Holdings sport a Zacks Rank #1 (Strong Buy), GATX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Hawaiian Holdings, Ryanair Holdings and GATX have gained more than 12%, 21% and 19%, respectively, in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>